Coronary Artery Disease
Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions

https://doi.org/10.1016/j.amjcard.2015.08.002Get rights and content

Comparative studies evaluating traditional versus newer antianginal (AA) medications in chronic stable angina pectoris (CSA) on cardiovascular (CV) outcomes and utilization are limited, particularly in patients with diabetes mellitus (DM). Claims data (2008 to 2012) were analyzed using a commercial database. Patients with CSA receiving a β blocker (BB), calcium channel blocker (CCB), long-acting nitrate (LAN), or ranolazine were identified and followed for 12 months after a change in AA therapy. Patients on traditional AA medications were required to have concurrent sublingual nitroglycerin. Therapy change was defined as adding or switching to another traditional AA medication or ranolazine to identify patients whose angina was inadequately controlled with previous therapy. Four groups were identified (BB, CCB, LAN, or ranolazine users) and matched on relevant characteristics. A DM subset was identified. Logistic regression compared revascularization at 30, 60, 90, 180, and 360 days. Negative binomial regression compared all-cause, CV-, and DM-related (in the DM cohort) health care utilization. A total of 8,008 patients were identified with 2,002 patients in each matched group. Majority were men (mean age 66 years). A subset of 3,724 patients with DM (BB, n = 933; CCB, n = 940; LAN, n = 937; and ranolazine, n = 914) resulted from this cohort. Compared to ranolazine in the overall cohort, traditional AA medication exhibited greater odds for revascularization and higher rates in all-cause outpatient, emergency room visits, inpatient length of stay, and CV-related emergency room visits. In the DM cohort, ranolazine demonstrated similar benefits over traditional AA medication. In conclusion, ranolazine use in patients with inadequately controlled chronic angina is associated with less revascularization and all-cause and CV-related health care utilization compared to traditional AA medication.

Section snippets

Methods

To compare differences between ranolazine and traditional AA therapies, we conducted a retrospective, quasi-experimental between-group analysis using propensity matching. The data source was the Clinformatics Data Mart representing a commercially available data source for research purposes from United Healthcare's nationwide patient population. The patient population included United Healthcare's fully insured, Medicaid, and Medicare Advantage population representing 49 million unique subjects.

Results

From January 1, 2008, through December 31, 2012, of those meeting the inclusion criteria, 8,008 were identified with CSA receiving either a BB (n = 2,002), CCB (n = 2,002), LAN (n = 2,002), or ranolazine (n = 2,002; Figure 2). As seen in Table 1, baseline characteristics were well matched between groups. Most patients were men, had a mean age of 66 years, and resided within the Southern United States. The type of medical coverage varied between therapeutic treatment groups. For private and

Discussion

As CSA is closely tied to coronary artery disease (CAD) and its complications, this particular CV condition has been associated with a large increase in health care resource utilization. In a post hoc analysis of the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation ACS–Thrombolysis in Myocardial Infarction 36 trial, Arnold et al7 found that compared to those without angina, patients with daily angina after an ACS event had a 2-fold increase in health care resource

Disclosures

Drs. Hartsfield and Koch are employed by Gilead Sciences. None of the other authors have conflicts of interest to disclose.

References (21)

There are more references available in the full text version of this article.

Cited by (0)

Funding: The present study was supported by a grant from Gilead Sciences, Foster City, California.

See page 1327 for disclosure information.

View full text